The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin
Abstract
Although statin drugs are generally efficacious for lowering plasma LDL-cholesterol levels, there is considerable variability in response. To identify candidate genes that may contribute to this variation, we used an unbiased genome-wide filter approach that was applied to 10,149 genes expressed in immortalized lymphoblastoid cell lines (LCLs) derived from 480 participants of the Cholesterol and Pharmacogenomics (CAP) clinical trial of simvastatin. The criteria for identification of candidates included genes whose statin-induced changes in expression were correlated with change in expression of HMGCR, a key regulator of cellular cholesterol metabolism and the target of statin inhibition. This analysis yielded 45 genes, from which RHOA was selected for follow-up because it has been found to participate in mediating the pleiotropic but not the lipid-lowering effects of statin treatment. RHOA knock-down in hepatoma cell lines reduced HMGCR, LDLR, and SREBF2 mRNA expression and increased intracellular cholesterol ester content as well as apolipoprotein B (APOB) concentrations in the conditioned media. Furthermore, inter-individual variation in statin-induced RHOA mRNA expression measured in vitro in CAP LCLs was correlated with the changes in plasma total cholesterol, LDL-cholesterol, and APOB induced by simvastatin treatment (40 mg/d for 6 wk) of the individuals from whom these cell lines were derived. Moreover, the minor allele of rs11716445, a SNP located in a novel cryptic RHOA exon, dramatically increased inclusion of the exon in RHOA transcripts during splicing and was associated with a smaller LDL-cholesterol reduction in response to statin treatment in 1,886 participants from the CAP and Pravastatin Inflamation and CRP Evaluation (PRINCE; pravastatin 40 mg/d) statin clinical trials. Thus, an unbiased filter approach based on transcriptome-wide profiling identified RHOA as a gene contributing to variation in LDL-cholesterol response to statin, illustrating the power of this approach for identifying candidate genes involved in drug response phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Association between RHOA haplotypes and expression of RHOA exon 2.5. (A) RHOA gene structure and location and sequence of exon 2.5. The 5′ and 3′ UTRs are indicated in solid grey, canonical exons are outlined in grey, and the novel exon is shown in red. The location of the three common RHOA exonic SNPs are shown. RNA-Seq libraries were prepared from HepG2, Hep3B, Huh7, and CAP LCLs (n = 3) and sequenced using 100 bp paired-end reads, and the novel exon was discovered by inspecting novel junction spanning reads. (B) Total RHOA expression levels and RHOA exon 2.5 levels were measured using qPCR, the percent containing exon 2.5 were calculated by dividing RHOA exon 2.5 levels by total RHOA levels, adjusted for batch effects using regression, and normal quantile transformed prior to association testing using linear regression. Graphs depict mean +/− SE. (C) CAP LCL cDNAs containing RHOA exon 2.5 were PCR-amplified and Sanger sequenced and the relative amounts of each allele of rs11716445 in exon 2.5 were estimated by measuring the height of the sequencing traces. (D) Representative sequencing traces of the LCL cDNA and genomic DNA of three heterozygous individuals from CAP illustrate that H3B is a cis-acting splicing QTL exhibiting allele-specific expression in RHOA exon 2.5 (rs11716445 and rs2878298) but not exon 5 (rs3448). H3B contains the minor allele [T] of rs11716445, H1 contains the minor allele [G] of rs2878298, and H2 contains the minor allele [A] of rs3448.](/paper-figures/612fdcf3db404d16bbe046a029f35a8b/rhoa-is-a-modulator-of-the-cholesterol-lowering-effects-of-statin-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although cellular phenotyping of LCLs has long been employed to functionalize the molecular impact of genetic variation associated with elevated cholesterol levels2-4, 6, 9, to our knowledge this is the first instance of capitalizing on the inter-individual variation of a cellular phenotype within LCLs to identify novel genes involved in cellular cholesterol homeostasis.”
From Transmembrane Protein 55B Is a Novel Regulator of Cellular Cholesterol Metabolism (2014) · cites this paper as [9]
In the citing paper
“Through expression array analysis of 480 in vitro simvastatin and sham incubated LCLs derived from participants of the Cholesterol and Pharmacogenetics (CAP) statin clinical trial, we recently reported the identification of RHOA as a novel candidate gene implicated in LDL-cholesterol lowering in response to statin treatment9.”
From Transmembrane Protein 55B Is a Novel Regulator of Cellular Cholesterol Metabolism (2014) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Cholesterol-Regulating Genes by Targeted RNAi Screening
Bartz, F., Kern, L., Erz, D., Zhu, M., Gilbert, D., Meinhof, T., Wirkner, U., Erfle, H., Muckenthaler, M., Pepperkok, R., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.05.009 · Cited by 198
Research works printed but not linked: 33
- D Altshuler, 2008, Genetic mapping in human disease, Science, 322, 881, 10.1126/science.1156409 · DOI · Paper page
- CI Amos, 2007, Successful design and conduct of genome-wide association studies, Hum Mol Genet, 16 Spec No. 2, R220, 10.1093/hmg/ddm161 · DOI
- JF Thompson, 2009, Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort, Circulation Cardiovascular Genetics, 2, 173, 10.1161/CIRCGENETICS.108.818062 · DOI · Paper page
- Y Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat Genet, 41, 1105, 10.1038/ng.449 · DOI · Paper page
- DI Chasman, 2012, Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial, Circ Cardiovasc Genet, 5, 257, 10.1161/CIRCGENETICS.111.961144 · DOI · Paper page
- JL Goldstein, 1990, Regulation of the mevalonate pathway, Nature, 343, 425, 10.1038/343425a0 · DOI · Paper page
- JL Goldstein, 1985, Receptor-mediated endocytosis: concepts emerging from the LDL receptor system, Annu Rev Cell Biol, 1, 1, 10.1146/annurev.cb.01.110185.000245 · DOI · Paper page
- MS Brown, 1985, The LDL receptor and HMG-CoA reductase–two membrane molecules that regulate cholesterol homeostasis, Curr Top Cell Regul, 26, 3, 10.1016/B978-0-12-152826-3.50008-5 · DOI
- JA Simon, 2006, Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study, Am J Cardiol, 97, 843, 10.1016/j.amjcard.2005.09.134 · DOI · Paper page
- P Guillaumot, 2010, Pdro, a protein associated with late endosomes and lysosomes and implicated in cellular cholesterol homeostasis, PLoS ONE, 5, e10977, 10.1371/journal.pone.0010977 · DOI
- K Okuhira, 2010, Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation, J Biol Chem, 285, 16369, 10.1074/jbc.M109.061424 · DOI
- DM Altshuler, 2010, Integrating common and rare genetic variation in diverse human populations, Nature, 467, 52, 10.1038/nature09298 · DOI · Paper page
- JC Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 · DOI · Paper page
- CA Argmann, 2005, Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux, J Biol Chem, 280, 22212, 10.1074/jbc.M502761200 · DOI
- DA Corey, 2007, Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts, Biochim Biophys Acta, 1772, 748, 10.1016/j.bbadis.2007.03.008 · DOI
- D Hoshino, 2009, A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation, actin remodeling, and matrigel invasion, J Biol Chem, 284, 27315, 10.1074/jbc.M109.041400 · DOI
- O Oliyarnyk, 2005, Interindividual differences of response to statin treatment cannot be explained by variations of the human gene for RhoA, Biochem Genet, 43, 143, 10.1007/s10528-005-1507-0 · DOI
- K Ihara, 1998, Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue, J Biol Chem, 273, 9656, 10.1074/jbc.273.16.9656 · DOI · Paper page
- K Rittinger, 1997, Structure at 1.65 A of RhoA and its GTPase-activating protein in complex with a transition-state analogue, Nature, 389, 758, 10.1038/39651 · DOI · Paper page
- PJ Smith, 2006, An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers, Hum Mol Genet, 15, 2490, 10.1093/hmg/ddl171 · DOI · Paper page
- S Chandradas, 2010, Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells, J Leukoc Biol, 87, 147, 10.1189/jlb.0409252 · doi:10.1189/jlb.0409252
- MW Medina, 2008, Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin, Circulation, 118, 355, 10.1161/CIRCULATIONAHA.108.773267 · DOI · Paper page
- RP Mason, 2005, Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions, Am J Cardiol, 96, 11F, 10.1016/j.amjcard.2005.06.008 · DOI
- MS Brown, 1978, Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase, J Biol Chem, 253, 1121, 10.1016/S0021-9258(17)38120-6 · DOI · Paper page
- LM Mangravite, Combined Influence of LDLR and HMGCR Sequence Variation on Lipid-Lowering Response to Simvastatin, Arterioscler Thromb Vasc Biol, 30, 1485, 10.1161/ATVBAHA.110.203273 · DOI · Paper page
- VG Tusher, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc Natl Acad Sci U S A, 98, 5116, 10.1073/pnas.091062498 · DOI · Paper page
- JT Leek, 2008, A general framework for multiple testing dependence, Proc Natl Acad Sci U S A, 105, 18718, 10.1073/pnas.0808709105 · DOI · Paper page
- F Innocenti, 2011, Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue, PLoS Genet, 7, e1002078, 10.1371/journal.pgen.1002078 · DOI · Paper page
- MW Medina, 2011, Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PLoS ONE, 6, e19420, 10.1371/journal.pone.0019420 · DOI
- M Barber, 2010, Genome-wide association of lipid-lowering response to statins in combined study populations, PLoS ONE, 5, e9763, 10.1371/journal.pone.0009763 · DOI · Paper page
- DI Chasman, 2004, Pharmacogenetic study of statin therapy and cholesterol reduction, Jama, 291, 2821, 10.1001/jama.291.23.2821 · DOI · Paper page
- AD Johnson, 2008, SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap, Bioinformatics, 24, 2938, 10.1093/bioinformatics/btn564 · DOI · Paper page
- L Cartegni, 2003, ESEfinder: A web resource to identify exonic splicing enhancers, Nucleic Acids Res, 31, 3568, 10.1093/nar/gkg616 · DOI · Paper page
Cited by
Sirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 691
Systems genetics approaches to understand complex traits
Civelek, M., & Lusis, A. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3575 · Cited by 621
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225
Blattmann, P., Henriques, D., Zimmermann, M., Frommelt, F., Sauer, U., Saez-Rodriguez, J., & Aebersold, R. (2017) · Cell Systems · doi:10.1016/j.cels.2017.11.002 · Cited by 26
Transmembrane Protein 55B Is a Novel Regulator of Cellular Cholesterol Metabolism
Medina, M. W., Bauzon, F., Naidoo, D., Theusch, E., Stevens, K., Schilde, J., Schubert, C., Mangravite, L. M., Rudel, L. L., Temel, R. E., et al. (2014) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302806 · Cited by 24
Self-citation
Metadata
- Authors
- Medina, M. W., Theusch, E., Naidoo, D., Bauzon, F., Stevens, K., Mangravite, L. M., Kuang, Y.-L., & Krauss, R. M.
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-11-15
- Volume
- 8
- Issue
- 11
- Pages
- e1003058
- ISSN
- 1553-7404
- PMC
- PMC3499361
- Cited by
- 41
- References
- 1
- Language
- en
- Update notices
- correction (2013-02-07)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. https://app.cochat.ai/papers/10.1371/journal.pgen.1003058
- The paper
- Medina, M. W., Theusch, E., Naidoo, D., Bauzon, F., Stevens, K., Mangravite, L. M., Kuang, Y.-L., & Krauss, R. M. (2012). RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. PLoS Genetics. https://doi.org/10.1371/journal.pgen.1003058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.